Name: in vitro synthesis of modified mrna for induction of protein expression in human cells
Uploaded: 2014-11-13T13:00:00
Description: Watch this Scientific Journal Video about In Vitro Synthesis of Modified mRNA for Induction of Protein Expression in Human Cells at JoVE.com

This project was funded by the European Social Funds in Baden-Wuerttemberg, Germany.

1. Augmentation of Plasmids Containing Required Coding DNA Sequences (CDS)
<ol>
	<li>Pre-warm SOC medium, which is included in the transformation kit, to room temperature and the LB agar plates containing 100 &#181;g/ml ampicillin to 37 &#176;C. Equilibrate the water bath to 42 &#176;C.</li>
	<li>Thaw one vial of chemically component E. coli on ice.</li>
	<li>Add 1-5 &#181;l of the plasmid (10 pg to 100 ng) containing the CDS into the vial of chemically component E. coli and mix gently. Do not mix the...

<ol>
	<li>Bangel-Ruland, N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=CFTR-mRNA+delivery:+a+novel+alternative+for+cystic+fibrosis+&amp;#34;gene+therapy&amp;#34;.">CFTR-mRNA delivery: a novel alternative for cystic fibrosis &amp;#34;gene therapy&amp;#34;.</a> The journal of gene medicine. , (2013).</li><li>Benteyn, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Design+of+an+Optimized+Wilms&amp;#34;+Tumor+1+(WT1)+mRNA+Construct+for+Enhanced+WT1+Expression+and+Improved+Immunogenicity+In+Vitro+and+In+Vivo.">Design of an Optimized Wilms&amp;#34; Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo.</a> Molecular therapy Nucleic acids. 2, 134 (2013).</li><li>Petsch, B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Protective+efficacy+of+in+vitro+synthesized,+specific+mRNA+vaccines+against+influenza+A+virus+infection.">Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.</a> Nature. 30, 1210-1216 (2012).</li><li>Mandal, P. K., Rossi, D. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Reprogramming+human+fibroblasts+to+pluripotency+using+modified+mRNA.">Reprogramming human fibroblasts to pluripotency using modified mRNA.</a> Nature protocols. 8, 568-582 (2013).</li><li>Warren, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Highly+efficient+reprogramming+to+pluripotency+and+directed+differentiation+of+human+cells+with+synthetic+modified+mRNA.">Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA.</a> Cell stem cell. 7, 618-630 (2010).</li><li>Yakubov, E., Rechavi, G., Rozenblatt, S., Givol, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Reprogramming+of+human+fibroblasts+to+pluripotent+stem+cells+using+mRNA+of+four+transcription+factors.">Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors.</a> Biochemical and biophysical research communications. 394, 189-193 (2010).</li><li>Anderson, B. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Incorporation+of+pseudouridine+into+mRNA+enhances+translation+by+diminishing+PKR+activation.">Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation.</a> Nucleic acids research. 38, 5884-5892 (2010).</li><li>Kariko, K., Buckstein, M., Ni, H., Weissman, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Suppression+of+RNA+recognition+by+Toll-like+receptors:+the+impact+of+nucleoside+modification+and+the+evolutionary+origin+of+RNA.">Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA.</a> Immunity. 23, 165-175 (2005).</li><li>Kariko, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Incorporation+of+pseudouridine+into+mRNA+yields+superior+nonimmunogenic+vector+with+increased+translational+capacity+and+biological+stability.">Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.</a> Molecular therapy : the journal of the American Society of Gene Therapy. 16, 1833-1840 (2008).</li><li>Kariko, K., Weissman, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Naturally+occurring+nucleoside+modifications+suppress+the+immunostimulatory+activity+of+RNA:+implication+for+therapeutic+RNA+development.">Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development.</a> Current opinion in drug discovery &amp; development. 10, 523-532 (2007).</li><li>Kormann, M. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Expression+of+therapeutic+proteins+after+delivery+of+chemically+modified+mRNA+in+mice.">Expression of therapeutic proteins after delivery of chemically modified mRNA in mice.</a> Nature biotechnology. 29, 154-157 (2011).</li><li>Hacein-Bey-Abina, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Insertional+oncogenesis+in+4+patients+after+retrovirus-mediated+gene+therapy+of+SCID-X1.">Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.</a> The Journal of clinical investigation. 118, 3132-3142 (2008).</li><li>Hacein-Bey-Abina, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Efficacy+of+gene+therapy+for+X-linked+severe+combined+immunodeficiency.">Efficacy of gene therapy for X-linked severe combined immunodeficiency.</a> The New England journal of medicine. 363, 355-364 (2010).</li><li>Avci-Adali, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Optimized+conditions+for+successful+transfection+of+human+endothelial+cells+with+in+vitro+synthesized+and+modified+mRNA+for+induction+of+protein+expression.">Optimized conditions for successful transfection of human endothelial cells with in vitro synthesized and modified mRNA for induction of protein expression.</a> Journal of biological engineering. 8, 8 (2014).</li></ol>

The mRNA therapy has tremendous potential in the field of regenerative medicine, treatment of diseases and vaccination. In this video, we demonstrate the production of a stabilized, modified mRNA for induction of protein expression in cells. Using this protocol, other desired mRNA can be generated. The in vitro synthesis of modified mRNA allows the transfection of cells with desired mRNAs to induce expression of target proteins. Thereby, the desired protein is expressed transiently under physiological conditions...

In cells, the transcription of messenger RNA (mRNA) and the following translation of mRNA into desired proteins ensure the proper functioning of cells. Hereditary or acquired genetic disorders can lead to insufficient and dysfunctional synthesis of proteins and cause severe diseases. Thus, a new therapeutic approach to induce the production of missing or defective proteins is the exogenous delivery of synthetic modified mRNA into cells, which codes for the desired protein. Thereby, cells are triggered to synthesize functional proteins, which they normally cannot produce or would naturally not need. Using this approach, genetic disorders can be corrected by introduction of mRNA that codes for the defective or missing protein 1. The mRNA therapy can also be used for vaccination to synthetize protein antigens, which are expressed by tumor cells or pathogens. Thereby, host immune system can be activated to effectively eliminate tumor cells or prevent infections 2,3. Furthermore, in recent years, mRNA was successfully used to generate induced pluripotent stem cells (iPSCs). For this purpose, fibroblasts were transfected with mRNAs to induce the expression of reprogramming factors 4-6 and to convert them in iPSCs with an enormous potential in regenerative medicine.
Previously, the use of conventional mRNA was associated with low stability and strong immunogenicity. Thus, clinical applications of conventional mRNAs were limited. However, the replacement of cytidine and uridine by 5-methylcytidine and pseudouridine within the mRNA molecule by Kariko and colleagues rendered mRNA molecules stable in biological fluids and dramatically reduced immune activation 7-10, which now allows the clinical applicability of modified mRNAs.
Using synthetically produced modified mRNAs, desired gene transcripts can be temporarily delivered in vivo 11 or in vitro to induce protein expression. The introduced mRNA is translated under physiological conditions by the cellular translation machinery. Due to lack of integration into the host cell genome compared to viral gene therapy vectors, the risk of oncogenesis is prevented 12,13. Thus, therapy using modified synthetic mRNA will get better clinical acceptance in the future.
Here, we describe a detailed protocol for production of modified mRNA (Figure 1), transfection of cells with mRNA and the evaluation of protein expression in transfected cells.

<table border="0" cellpadding="0" cellspacing="0" width="1058">
	<tbody>
		<tr height="21">
			<td height="21" style="height:21px;width:295px;">Name of Material/ Equipment</td>
			<td style="width:157px;">Company</td>
			<td style="width:172px;">Catalog Number</td>
			<td style="width:435px;">Comments/Description</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:295px;">Cell culture</td>
			<td style="width:157px;"></td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">DMEM, high glucose</td>
			<td>PAA</td>
			<td>E15-009</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">FBS</td>
			<td>Life Technologies</td>
			<td>10500</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Penicillin/Streptomycin&#160;</td>
			<td style="width:157px;">PAA</td>
			<td>P11-010</td>
			<td>100x</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">L-glutamine&#160;</td>
			<td>PAA</td>
			<td>M11-004</td>
			<td>200 mM</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">DPBS without calcium and magnesium&#160;</td>
			<td>PAA</td>
			<td>E15-002</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">0.04% Trypsin / 0.03% EDTA&#160;</td>
			<td>Promocell</td>
			<td>C-41020</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;">TNS</td>
			<td>Promocell</td>
			<td>C-41120</td>
			<td style="width:435px;">Trypsin Neutralizing Solution, 0.05% trypsin inhibitor in 0.1% BSA</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">HEK-293 cells</td>
			<td style="width:157px;">ATCC</td>
			<td>CRL-1573</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:295px;"></td>
			<td style="width:157px;"></td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Consumables</td>
			<td style="width:157px;"></td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Tissue culture plates, 12-well&#160;</td>
			<td>Corning</td>
			<td>3512</td>
			<td></td>
		</tr>
		<tr height="24">
			<td height="24" style="height:24px;">Cell culture flask (75 cm2)&#160;</td>
			<td>Corning</td>
			<td>430641</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:295px;">DNase-and RNase-free 1.5 ml sterile microcentrifuge tubes&#160;</td>
			<td>Eppendorf</td>
			<td>0030 121.589</td>
			<td>Safe-Lock, Biopur</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">15 ml conical tubes&#160;</td>
			<td>greiner bio-one</td>
			<td>188271</td>
			<td></td>
		</tr>
		<tr height="63">
			<td height="63" style="height:63px;width:295px;">PCR clean and sterile epT.I.P.S. dualfilter pipette tips&#160;</td>
			<td>Eppendorf</td>
			<td style="width:172px;">10 &#181;l: 022491202,&#160;&#160;&#160; 100 &#181;l: 022491237, 1000 &#181;l: 022491253</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Cryovial</td>
			<td>greiner bio-one</td>
			<td>122279-128</td>
			<td>Cryo.s&#160;</td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:295px;">14 ml polypropylene round bottom tube for bacterial culture&#160;</td>
			<td>BD Falcon</td>
			<td>352059</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:295px;"></td>
			<td style="width:157px;"></td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Plasmid amplification and purification</td>
			<td style="width:157px;"></td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">pcDNA 3.3_eGFP Plasmid&#160;</td>
			<td style="width:157px;">Addgene</td>
			<td>26822</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:295px;">One Shot Top10 chemically component Escherichia coli&#160;</td>
			<td>Invitrogen</td>
			<td>C4040-10</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:295px;">Sterile water (Ampuwa)</td>
			<td>Fresenius Kabi</td>
			<td>1636071</td>
			<td></td>
		</tr>
		<tr height="24">
			<td height="24" style="height:24px;">LB medium (Luria/Miller)&#160;</td>
			<td>Carl Roth</td>
			<td>X968.1</td>
			<td>Dissolve 25 g l-1 in sterile water.</td>
		</tr>
		<tr height="24">
			<td height="24" style="height:24px;">LB agar (Luria/Miller)&#160;</td>
			<td>Carl Roth</td>
			<td>X969.1</td>
			<td>Dissolve 40 g l-1 in sterile water.</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Ampicillin Ready Made Solution</td>
			<td>Sigma Aldrich</td>
			<td>A5354</td>
			<td>100 mg/ml&#160;</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Glycerol</td>
			<td>Sigma Aldrich</td>
			<td>G2025</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">QIAprep Spin Miniprep Kit&#160;</td>
			<td>Qiagen</td>
			<td>27104</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:295px;"></td>
			<td style="width:157px;"></td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">mRNA production</td>
			<td style="width:157px;"></td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">HotStar HiFidelity Polymerase Kit&#160;</td>
			<td>Qiagen</td>
			<td>202602</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">QIAquick PCR Purification Kit&#160;</td>
			<td>Qiagen</td>
			<td>28106</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">MEGAscript T7 Kit&#160;</td>
			<td>Life Technologies</td>
			<td>AM1334</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">5-Methylcytidine-5&#180;-triphosphate&#160;</td>
			<td>Trilink</td>
			<td>N1014</td>
			<td>5-Methyl-CTP</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Pseudouridine-5&#180;-triphosphate&#160;</td>
			<td>Trilink</td>
			<td>N1019</td>
			<td>Pseudo-UTP</td>
		</tr>
		<tr height="45">
			<td height="45" style="height:45px;width:295px;">3&#180;-O-Me-m7G(5&#180;)ppp(5`)G RNA cap structure analog&#160;</td>
			<td>New England Biolabs</td>
			<td>S1411L</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">RiboLock RNase Inhibitor</td>
			<td>Thermo Scientific</td>
			<td>EO0381</td>
			<td>40 U/&#181;l&#160;</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">TURBO DNase</td>
			<td>Life Technologies</td>
			<td>AM1334</td>
			<td>2 U/&#181;l (from MEGAscript T7 Kit)</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Antarctic phosphatase&#160;</td>
			<td>New England Biolabs</td>
			<td>MO289S</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">RNeasy mini kit&#160;</td>
			<td>Qiagen</td>
			<td>74104</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">RNaseZap solution&#160;</td>
			<td>Life Technologies</td>
			<td>AM9780</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:295px;"></td>
			<td style="width:157px;"></td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Transfection</td>
			<td style="width:157px;"></td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Lipofectamine 2000 Transfection Reagent&#160;</td>
			<td>Invitrogen</td>
			<td>11668-019</td>
			<td>Cationic lipid transfection reagent</td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;">Opti-MEM I Reduced Serum Media&#160;</td>
			<td>Invitrogen</td>
			<td>11058-021</td>
			<td style="width:435px;">Improved Minimal Essential Medium (MEM) with&#160; reduced Fetal Bovine Serum (FBS) supplementation&#160;</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:295px;"></td>
			<td style="width:157px;"></td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Gel electrophoresis</td>
			<td style="width:157px;"></td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Agarose</td>
			<td>Sigma-Aldrich</td>
			<td>A9539</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Gelred Nucleic Acid Gel Stain</td>
			<td>Biotium</td>
			<td>41003</td>
			<td>10,000x in water&#160;</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">peqGOLD Range Mix DNA-Ladder&#160;</td>
			<td>Peqlab</td>
			<td>25-2210</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">0.5-10 kb RNA Ladder&#160;</td>
			<td>Invitrogen</td>
			<td>15623-200</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">1x TBE buffer</td>
			<td style="width:157px;"></td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:295px;"></td>
			<td style="width:157px;"></td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Flow cytometry analyses</td>
			<td style="width:157px;"></td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">CellFIX (1x)</td>
			<td>BD Biosciences</td>
			<td>340181</td>
			<td>10x concentrate&#160;</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:295px;"></td>
			<td style="width:157px;"></td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:295px;">Primer for insert amplification and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; poly (T) tail PCR</td>
			<td style="width:157px;"></td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Forward Primer (HPLC-grade) 10 &#181;M</td>
			<td style="width:157px;">Ella Biotech</td>
			<td style="width:172px;"></td>
			<td>5&#180;-TTGGACCCTCGTACAGAAGCTAATACG-3&#180;</td>
		</tr>
		<tr height="25">
			<td height="25" style="height:25px;">Reverse Primer (HPLC-grade) 10 &#181;M</td>
			<td style="width:157px;">Ella Biotech</td>
			<td style="width:172px;"></td>
			<td>5&#180;- T120-CTTCCTACTCAGGCTTTATTCAAAGACCA-3&#180;</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:295px;"></td>
			<td style="width:157px;"></td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Equipment</td>
			<td style="width:157px;"></td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="25">
			<td height="25" style="height:25px;">Cell incubator</td>
			<td>Binder</td>
			<td style="width:172px;"></td>
			<td>CO2 (5%) and O2 (20%)&#160;</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">CASY cell counter&#160;</td>
			<td>Sch&#228;rfe System</td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="44">
			<td height="44" style="height:44px;">Sterile workbench&#160;</td>
			<td style="width:157px;">BDK Luft-und Reinraumtecknik GmbH</td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Bacterial incubator&#160;</td>
			<td>Incutec</td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Water bath</td>
			<td style="width:157px;"></td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">ScanDrop spectrophotometer&#160;</td>
			<td>Analytic Jena</td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">PCR thermocycler&#160;</td>
			<td>Eppendorf</td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Microcentrifuge</td>
			<td>Eppendorf</td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Vortex</td>
			<td>peqlab</td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Thermomixer</td>
			<td>Eppendorf</td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Gel apparatus for electrophoresis&#160;</td>
			<td>Bio-Rad</td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Gel documentation system&#160;</td>
			<td>Bio-Rad</td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">FACScan System&#160;</td>
			<td>BD Biosciences</td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Fluorescence microscope&#160;</td>
			<td>Nikon</td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Phase-contrast microscope&#160;</td>
			<td>Zeiss</td>
			<td style="width:172px;"></td>
			<td></td>
		</tr>
	</tbody>
</table>

in vitro synthesis of modified mrna for induction of protein expression in human cells

The exogenous delivery of coding synthetic messenger RNA (mRNA) for induction of protein synthesis in desired cells has enormous potential in the fields of regenerative medicine, basic cell biology, treatment of diseases, and reprogramming of cells. Here, we describe a step by step protocol for generation of modified mRNA with reduced immune activation potential and increased stability, quality control of produced mRNA, transfection of cells with mRNA and verification of the induced protein expression by flow cytometry. Up to 3 days after a single transfection with eGFP mRNA, the transfected HEK293 cells produce eGFP. In this video article, the synthesis of eGFP mRNA is described as an example. However, the procedure can be applied for production of other desired mRNA. Using the synthetic modified mRNA, cells can be induced to transiently express the desired proteins, which they normally would not express.

Using a pcDNA 3.3 plasmid containing the CDS of eGFP, the synthesis of modified eGFP mRNA was established (Figure 1). After insert amplification by PCR and poly T-tailing, a clear band with a length of approximately 1,100 bp is detected (Figure 2). Increasing the IVT time augmented the yield of mRNA (Figure 3). After the IVT, a clear mRNA band with a length of approximately 1,100 bp was detected, which corresponds to the length of eGFP mRNA to be produced (Figure...

Watch this Scientific Journal Video about In Vitro Synthesis of Modified mRNA for Induction of Protein Expression in Human Cells at JoVE.com

In Vitro Synthesis of Modified mRNA for Induction of Protein Expression in Human Cells

In this video article, we describe the in vitro synthesis of modified mRNA for induction of protein expression in cells.

In Vitro Synthesis of Modified mRNA for Induction of Protein Expression in Human Cells

The exogenous delivery of coding synthetic messenger RNA (mRNA) for induction of protein synthesis in desired cells has enormous potential in the fields ...

Research

JoVE Journal

Biology

Staining of Proteins in Gels with Coomassie G-250 without Organic Solvent and Acetic Acid

In classical protein staining protocols using Coomassie Brilliant Blue (CBB), solutions with high contents of toxic and flammable organic solvents ...

Purification of the M. magneticum Strain AMB-1 Magnetosome Associated Protein MamA&Delta;41

Magnetotactic bacteria comprise a diverse group of aquatic microorganisms that are able to orientate themselves along geomagnetic fields. This behavior is ...

In vitro Reconstitution of the Active T. castaneum Telomerase

In vitro Reconstitution of the Active T. castaneum Telomerase

Efforts to isolate the catalytic subunit of telomerase, TERT, in sufficient quantities for structural studies, have been met with limited success for more ...

Efficient Derivation of Human Cardiac Precursors and Cardiomyocytes from Pluripotent Human Embryonic Stem Cells with Small Molecule Induction

To date, the lack of a suitable human cardiac cell source has been the major setback in regenerating the human myocardium, either by cell-based ...

Isolation of Ribosome Bound Nascent Polypeptides in vitro to Identify Translational Pause Sites Along mRNA

Isolation of Ribosome Bound Nascent Polypeptides in vitro to Identify Translational Pause Sites Along mRNA

The rate of translational elongation is non-uniform. mRNA secondary structure, codon usage and mRNA associated proteins may alter ribosome movement on the ...

Efficient Generation Human Induced Pluripotent Stem Cells from Human Somatic Cells with Sendai-virus

A few years ago, the establishment of human induced pluripotent stem cells (iPSCs) ushered in a new era in biomedicine. Potential uses of human iPSCs ...

Profiling Individual Human Embryonic Stem Cells by Quantitative RT-PCR

Heterogeneity of stem cell population hampers detailed understanding of stem cell biology, such as their differentiation propensity toward different ...

Analysis of Global RNA Synthesis at the Single Cell Level following Hypoxia

Hypoxia or lowering of the oxygen availability is involved in many physiological and pathological processes. At the molecular level, cells initiate a ...

siRNA Screening to Identify Ubiquitin and Ubiquitin-like System Regulators of Biological Pathways in Cultured Mammalian Cells

Post-translational modification of proteins with ubiquitin and ubiquitin-like molecules (UBLs) is emerging as a dynamic cellular signaling network that ...

Green Fluorescent Protein-based Expression Screening of Membrane Proteins in Escherichia coli

Green Fluorescent Protein-based Expression Screening of Membrane Proteins in Escherichia coli

The production of recombinant membrane proteins for structural and functional studies remains technically challenging due to low levels of expression and ...